Novel application of ankyrin repeat domain-containing 13A gene and/or protein encoded by the same

A repeat domain and ankyrin technology, applied in the field of biomedicine, can solve problems such as insufficient research and molecular targeted drugs that are difficult to meet clinical treatment, and achieve highly relevant effects

Pending Publication Date: 2020-03-31
SHANDONG UNIV QILU HOSPITAL
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research on the mechanism of AML is still insufficient, and the existing molecular targeted drugs are difficult to meet the needs of clinical treatment. Therefore, mining and searching for new key pathogenic molecules and potential intervention targets in the occurrence and development of AML will provide a basis for diagnosis and treatment stratification and prognosis. Assessment provides new evidence of critical clinical importance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of ankyrin repeat domain-containing 13A gene and/or protein encoded by the same
  • Novel application of ankyrin repeat domain-containing 13A gene and/or protein encoded by the same
  • Novel application of ankyrin repeat domain-containing 13A gene and/or protein encoded by the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Screening and validation of acute myeloid leukemia prognostic marker molecule Ankrd13A

[0020] 1. Materials and methods

[0021] 1 Bioinformatics data analysis tools

[0022] 1.1 Cancer and Tumor Gene Atlas (The Cancer Genome Atlas, TCGA)

[0023] The TCGA project is invested by the U.S. government. It aims to use genome sequencing technology to map all human cancer genome variations and conduct comparative analysis to study the relationship between RNA and protein expression, DNA copy number changes, and patient prognosis. . So far, more than 30 kinds of human tumor data have been included in the TCGA database, which is of great significance for the diagnosis and treatment of tumors including AML.

[0024] 1.2 Gene Expression Omnibus (GEO) database

[0025] GEO is an international public database containing high-throughput gene expression and other functional genomics data. It is supported and maintained by the National Center for Biotechnology Informati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses novel application of an ankyrin repeat domain-containing 13A gene and / or a protein encoded by the same. An acute myeloid leukemia (AML) diagnosis and prognosis related molecular marker is screened to obtain an ankyrin repeat domain-containing 13A gene(ANKRD13A) closely related to AML patient prognosis; the high expression of ANKRD13A in the body of an AML patient warns poorprognosis; the ANKRD13A can be used as an independent factor for influencing the prognosis of the AML patient; the ANKRD13A is related to the FAB typing and the cytogenetics risk stratification of the AML patient; and the ANKRD13A may participate in the disease progression of AML through a variety of pathways. The ANKRD13A can be used for preparing a therapeutic drug or a prognosis detection reagent for the acute myeloid leukemia.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a new application of ankyrin repeat domain 13A gene and / or its encoded protein. Background technique [0002] Acute myeloid leukemia (AML) is a malignant clonal disease originating from hematopoietic stem / progenitor cells, which is mainly characterized by uncontrolled proliferation, apoptosis arrest, and differentiation arrest of myeloid primitive and immature cells, thereby inhibiting normal hematopoiesis , and cause extramedullary infiltration. The pathogenesis of AML is complicated and the clinical prognosis is poor. Although most patients can achieve complete remission (CR) with combination chemotherapy, only a few special types of AML patients can survive for a long time, and most patients develop disease within 3 years after CR. Relapse, refractory or relapsed patients have poor chemotherapy effect, and the types of targeted drugs for AML are also very limited. Ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/68G01N33/574A61K48/00A61K38/17A61P35/02
CPCC12Q1/6886G01N33/68G01N33/57426A61K48/005A61K38/1709A61P35/02C12Q2600/106C12Q2600/118G01N2800/52
Inventor 陈春燕付悦徐曼李淼董玉婷
Owner SHANDONG UNIV QILU HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap